Drug intelligence / Profile preview

RLD2007

Development stage: Phase 1
Lead developer: Hanmi Pharmaceutical
Administration: Oral

Overview

RLD2007 is an investigational drug developed by Hanmi Pharmaceutical. It is currently in Phase 1 clinical development, with studies focused on evaluating its safety, pharmacokinetics, and drug-drug interactions in healthy volunteers. The specific mechanism of action, molecular target(s), therapeutic area(s), and active indication(s) for RLD2007 have not been publicly disclosed as of the latest available data. Clinical trials have involved oral administration and co-administration with another investigational agent (RLD2301 or HCP1902) to assess interaction profiles[1][2][6].

Beyond the preview

Go deeper on RLD2007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2007.

Explore the full profile